Business Wire
18 Nov 2026, 11:45 UTC · 1h ago
Pfizer Enters into Exclusive Licensing Agreement with Starna Therapeutics for Autoimmune Diseases
Impact · against what's priced in
Pfizer's acquisition of three pre-IND CAR-T programs for autoimmune diseases adds early-stage optionality to its pipeline. While promising, the pre-IND status means these assets are years from commercialization and provide only a marginal near-term catalyst.
- PFE+0.20
No priced-in read yet





